Skip to main navigation Skip to search Skip to main content

NCCN Guidelines® Insights: Thyroid Carcinoma, Version 1.2025

  • Robert I. Haddad
  • , Lindsay Bischoff
  • , Megan Applewhite
  • , Victor Bernet
  • , Erik Blomain
  • , Maria Brito
  • , Naifa Lamki Busaidy
  • , Michael Campbell
  • , Olivia Delozier
  • , Quan-Yang Duh
  • , Hormoz Ehya
  • , Erin Grady
  • , Theresa Guo
  • , Megan Haymart
  • , Jason P. Hunt
  • , Fouad Kandeel
  • , Anupam Kotwal
  • , Dominick M. Lamonica
  • , Jochen Lorch
  • , Susan J. Mandel
  • Stephanie Markovina, Wojciech Mydlarz, Lisle Nabell, Christopher D. Raeburn, Rod Rezaee, John A. Ridge, Hadley Ritter, Mara Y. Roth, Sarimar Agosto Salgado, Randall P. Scheri, Jatin P. Shah, Jennifer A. Sipos, Rebecca Sippel, Cord Sturgeon, Lori J. Wirth, Richard J. Wong, Francis Worden, Michael W. Yeh, Susan Darlow, Carly J. Cassara, Bailee Sliker
  • Fox Chase Cancer Center

Research output: Contribution to journal › Article › peer-review

48 Scopus citations

Abstract

The NCCN Guidelines for Thyroid Carcinoma address the management of different types of thyroid carcinoma, including papillary, follicu-lar, oncocytic, medullary, and anaplastic carcinoma. The NCCN Thyroid Carcinoma Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommen-dations. These NCCN Guidelines Insights focus on the panel’s most recent recommendations regarding systemic therapies for thyroid carcinoma as well as the supporting clinical data.

Original languageEnglish
Article numbere250033
Number of pages10
JournalJournal of the National Comprehensive Cancer Network
Volume23
Issue number7
DOIs
StatePublished - Jul 2025

Keywords

  • Humans
  • Medical Oncology/standards
  • Thyroid Neoplasms/therapy

Fingerprint

Dive into the research topics of 'NCCN Guidelines® Insights: Thyroid Carcinoma, Version 1.2025'. Together they form a unique fingerprint.

Cite this